Compare Gold Fields Limited (GFI) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gold Fields Limited vs Recursion Pharmaceuticals Inc — how do they compare? Gold Fields Limited trades at $36.85 (market cap $31.87B), while Recursion Pharmaceuticals Inc trades at $4.33 (market cap $2.14B). The key difference: Gold Fields Limited is far larger — about 14.9× Recursion Pharmaceuticals Inc's market cap, and Gold Fields Limited pays a 6% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gold Fields Limited for 49 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| GFI | RXRX | |
|---|---|---|
Market Cap | $31.87B | $2.14B |
Volume | 4,169,651 | 30,789,535 |
Sector | Basic Materials | Health |
52-Week High | $61.52 | $6.79 |
52-Week Low | $31.25 | $2.84 |
Typical Hold Time | 49 Days | 23 Days |
Enterprise Value | $32.47B | $1.66B |
Dividend Yield | 6% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gold Fields (GFI) trades at $36.82, up 5.05% today, amid mixed technical signals with a bearish overall trend. Fundamentally, the company shows strong profitability with 38.66% net margins and robust cash flow generation of $3.77B from operations in 2025. Recent news highlights the rejected $27B Northern Star takeover bid and strong operational performance from Salares Norte, driving investor attention to the company's capital allocation strategy.
The investment outlook balances strong fundamentals against acquisition risks and technical weakness. With 44% analyst buy ratings and a $52.75 price target suggesting 43% upside, GFI presents value opportunity, though recent earnings misses and bearish technicals warrant caution. Key risks include execution on growth projects and gold price volatility.
RXRX trades at $4.255, down 0.35% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $644.76 million in 2025 on $74.26 million revenue, with a negative net income margin of -961.97%. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI announced September 21, 2026, and pipeline progress presented at the Morgan Stanley Healthcare Conference.
The outlook remains speculative, driven by AI-powered drug discovery potential and partnership milestones, but significant execution risk persists due to heavy losses and high cash burn. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for long-term platform value against near-term financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gold Fields Limited
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Read more on GFI →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
